Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

Summary

The purpose of this study is to assess the effect of Tekturna (aliskiren), in combination with an ACE and calcium channel blocker in hypertensive patients diagnosed with Type II diabetes.

Timeline

Start

2009-08

Primary completion

2012-12

Completion

2012-12

Outcome

Outcome not reported

Stopped: “Due to safety concerns re: the concomitant use of aliskiren with an ACEi or ARB.”

Drugs

Indications